Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07389590 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

Name: Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis — clinical trial record (NCT07389590)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorJohns Hopkins University

Started2026-02-10

View on ClinicalTrials.gov ↗

Amendment history

2026-05-01

Study Status, Outcome Measures, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-02→confirmed 2026-02-10

Secondary endpointsdetails revised at 1 of 1 entry

Study sitesdetails revised at 1 of 1 site

2026-02-04

Original filing

Johns Hopkins University

505 trials monitored

See 47 trials at risk

Multiple Sclerosis

987 trials monitored

See 31 trials at risk

The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.

Trial Details

NCT Number	NCT07389590
Lead Sponsor	Johns Hopkins University Collaborators: TG Therapeutics, Inc.
Conditions	Multiple Sclerosis
Enrollment	50 participants
Start Date	2026-02-10
Primary Completion	2028-10 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2026-05-06